Moving towards biologically informed treatment strategies for T-cell lymphomas Review
| Authors: | Stuver, R.; Lewis, N.; Dogan, A.; Horwitz, S. M. |
| Review Title: | Moving towards biologically informed treatment strategies for T-cell lymphomas |
| Abstract: | The rarity and biological heterogeneity of the peripheral T-cell lymphomas has made subtype- and biomarker-driven approaches challenging to realize and even more challenging to evaluate in clinical practice. Out of necessity, treatment of T-cell lymphomas has historically been derivative of other aggressive lymphomas, utilizing intensive combination chemotherapy programs in the upfront setting and non-overlapping cytotoxic regimens upon relapse. However, due to tremendous work in understanding the oncogenic basis of these varied diseases, an increasing exploration of rational, targeted therapies is underway. Still, clinical successes have at times lagged behind pathobiological realizations, and there is an evolving need for biologically based, subtype-specific strategies in the clinic. Herein we propose a framework for future success that relies upon optimizing standard therapy in populations known to benefit from combination chemotherapy, building upon CHOP (or CHOP-like) induction with the CHOP + X model, exploring the use of targeted platforms in the relapsed and refractory setting, and designing biomarker-informed clinical trials that target-specific subhistologies and unique molecular subsets. © 2022, Japanese Society of Hematology. |
| Keywords: | prednisone; cancer recurrence; doxorubicin; cancer combination chemotherapy; antineoplastic agents; antineoplastic agent; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; cyclophosphamide; vincristine; hematopoietic stem cell transplantation; cancer resistance; cutaneous t-cell lymphoma; cutaneous t cell lymphoma; peripheral t cell lymphoma; t cell lymphoma; epigenetics; tumor recurrence; t-cell lymphoma; cd30 ligand; peripheral t-cell lymphoma; lymphoma, t-cell, peripheral; anaplastic large cell lymphoma; crizotinib; angioimmunoblastic t cell lymphoma; anaplastic large-cell lymphoma; brentuximab vedotin; ruxolitinib; humans; human; article; pembrolizumab; jak-stat signaling; tfh cell; mogamulizumab; pumactant |
| Journal Title: | International Journal of Hematology |
| Volume: | 117 |
| Issue: | 4 |
| ISSN: | 0925-5710 |
| Publisher: | Springer Japan KK |
| Date Published: | 2023-04-01 |
| Start Page: | 492 |
| End Page: | 503 |
| Language: | English |
| DOI: | 10.1007/s12185-022-03524-4 |
| PUBMED: | 36574170 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Erratum issued, see DOI: [10.1007/s12185-023-03565-3] -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work